<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN">
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=UTF-8">
    <title>Description of Interventions_2</title>
    <link href="data:image/x-icon;base64,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" rel="icon" type="image/x-icon">
    <style>@import "https://fonts.googleapis.com/css?family=Source+Sans+Pro:ital,wgth:0,400;0,700;1,400;1,700";body {  font-family: "Source Sans Pro", sans-serif;  margin: 40px;}@media screen {  #backToTop {    position: fixed;    bottom: 0px;    left: 50%;    transform: translateX(-50%);    border-radius: 4px 4px 0 0;    padding: 4px 12px 4px 12px;    background: #1f3c73;    font-weight: bold;  }  #backToTop a {    color: white;  }}@media print {  #backToTop {    display: none;  }}table {  width: fit-content;  border-collapse: collapse;}th {  font-weight: bold;  background: LightGray;}td, th {  border: 1px solid LightGray;  padding: 8px;  font-size: 14px;  vertical-align: top;}caption {  font-weight: bold;  font-size: large;  text-align: left;  padding: 8px;}h1 {  font-size:38.5px;}h2 {  font-size:31.5px;}h1 small, h3 {  font-size:24.5px;}h2 small, h4 {  font-size:17.5px;}h3 small, h4 small, h5 {  font-size:14px;}h6 {  font-size:11.9px;}a {  color: #002d64;  text-decoration: none;}.byline {  font-weight: bold;  color: #002D64;}.disclaimer {  font-style: italic;}figure, table.analysis {  width: fit-content;  display: block;  margin-block-start: 1em;  margin-block-end: 1em;  margin-inline-start: 40px;  margin-inline-end: 40px;}thead tr td, th, figcaption, caption {  font-weight: bold;  background: LightGray;}span.inserted {  background-color: #e5ffcd;}span.deleted {  background-color: #e5ffcd;  text-decoration: line-through;}span.marker-yellow {  background-color: #ffff80;}ol ol {  list-style-type: lower-alpha;}ol ol ol {  list-style-type: lower-roman;}</style>
  </head>
  <body>
    <div class="logo">
      <svg xmlns="http://www.w3.org/2000/svg" height="57" viewBox="0 0 1138.5 192" width="338" xml:space="preserve">
        <path d="M86 .5v33a63.3 63.3 0 0 0 0 125v33a96 96 0 0 1 0-191zM106 .5v33a63.3 63.3 0 0 1 0 125v33a96 96 0 0 0 0-191z" fill="#1f3c73"></path>
        <path d="M93 0h6v192h-6z" fill="#a53995"></path>
        <path d="M93 0h6v192h-6zM82 44h8v6h-8z" fill="#a53995"></path>
        <path d="M63 58h40v6H63zM69 73h30v6H69zM78 86h36v6H78zM63 100h42v6H63zM60 114h28v6H60zM88 128h15v6H88zM84 140l6 6-6 6-6-6z" fill="#a53995"></path>
        <g aria-label="Cochrane" fill="#1f3c73" stroke-width="3.368">
          <path d="M256.96 82.722q-7.366 0-13.564-3.413-6.198-3.414-9.97-10.06-3.683-6.737-3.683-16.528 0-9.701 3.772-16.528 3.863-6.917 10.15-10.51 6.378-3.682 13.743-3.682 5.66 0 10.15 2.335 4.492 2.246 7.456 5.3l-7.007 8.443q-2.245-2.066-4.76-3.323-2.426-1.347-5.57-1.347-3.952 0-7.275 2.245-3.234 2.246-5.21 6.468-1.886 4.221-1.886 10.15 0 8.982 3.862 14.013 3.863 5.03 10.33 5.03 3.593 0 6.378-1.617 2.874-1.617 5.03-3.863l7.006 8.264q-7.365 8.624-18.953 8.624zM302.86 82.722q-5.659 0-10.689-2.695-4.94-2.784-7.994-7.994-3.054-5.3-3.054-12.665 0-7.456 3.054-12.665 3.054-5.21 7.994-7.905 5.03-2.784 10.689-2.784t10.599 2.784q4.94 2.695 7.994 7.905 3.054 5.21 3.054 12.665 0 7.365-3.054 12.665-3.054 5.21-7.994 7.994-4.94 2.695-10.599 2.695zm0-10.689q4.042 0 6.108-3.413 2.066-3.504 2.066-9.252 0-5.839-2.066-9.252-2.066-3.413-6.108-3.413-4.132 0-6.198 3.413-1.976 3.413-1.976 9.252 0 5.749 1.976 9.252 2.066 3.413 6.198 3.413zM352.98 82.722q-6.198 0-11.228-2.695-4.94-2.784-7.905-7.994-2.874-5.3-2.874-12.665 0-7.456 3.234-12.665 3.233-5.21 8.533-7.905 5.3-2.784 11.408-2.784 4.132 0 7.276 1.347 3.234 1.348 5.749 3.413l-6.198 8.534q-3.144-2.605-6.018-2.605-4.761 0-7.636 3.413-2.784 3.413-2.784 9.252 0 5.749 2.784 9.252 2.875 3.413 7.186 3.413 2.156 0 4.222-.898 2.066-.988 3.773-2.335l5.21 8.623q-3.324 2.874-7.186 4.132-3.863 1.167-7.546 1.167zM375.53 81.644V18.677h13.204v15.45l-.629 7.994q2.515-2.245 5.839-4.131 3.413-1.977 7.904-1.977 7.276 0 10.51 4.85 3.323 4.762 3.323 13.115v27.666h-13.204v-25.96q0-4.85-1.347-6.646-1.258-1.797-4.132-1.797-2.515 0-4.312 1.168-1.796 1.078-3.952 3.144v30.091zM426.82 81.644V37.091h10.779l.898 7.815h.36q2.425-4.491 5.838-6.647 3.413-2.246 6.827-2.246 1.886 0 3.144.27 1.257.18 2.156.628l-2.156 11.408q-1.168-.359-2.336-.539-1.078-.18-2.515-.18-2.515 0-5.3 1.887-2.694 1.797-4.49 6.288v25.869zM471.28 82.722q-6.108 0-9.701-3.862-3.593-3.953-3.593-9.612 0-7.006 5.928-10.959 5.929-3.952 19.133-5.3-.18-2.964-1.796-4.67-1.527-1.797-5.21-1.797-2.785 0-5.659 1.078-2.874 1.078-6.108 2.964l-4.76-8.713q4.221-2.605 8.982-4.222 4.85-1.616 10.06-1.616 8.533 0 13.114 4.94 4.58 4.94 4.58 15.18v25.51h-10.778l-.898-4.581h-.36q-2.784 2.515-6.018 4.132-3.144 1.527-6.916 1.527zm4.491-10.24q2.246 0 3.863-.988 1.706-1.078 3.413-2.785v-7.814q-7.006.898-9.701 2.874-2.695 1.886-2.695 4.491 0 2.156 1.348 3.234 1.437.988 3.772.988zM507.39 81.644V37.091h10.779l.898 5.659h.36q2.874-2.695 6.287-4.671 3.503-2.066 7.995-2.066 7.275 0 10.509 4.85 3.323 4.761 3.323 13.115v27.666h-13.204v-25.96q0-4.85-1.347-6.646-1.258-1.797-4.132-1.797-2.515 0-4.312 1.168-1.796 1.078-3.952 3.144v30.09zM578.71 82.722q-6.378 0-11.498-2.785-5.12-2.784-8.084-7.994-2.964-5.21-2.964-12.575 0-7.276 2.964-12.486 3.054-5.21 7.904-7.994 4.85-2.875 10.15-2.875 6.378 0 10.51 2.875 4.221 2.784 6.287 7.635 2.156 4.76 2.156 10.869 0 1.706-.18 3.413-.18 1.617-.36 2.425h-26.677q.898 4.85 4.042 7.186 3.144 2.246 7.545 2.246 4.761 0 9.612-2.964l4.4 7.994q-3.412 2.335-7.634 3.683-4.222 1.347-8.174 1.347zm-9.88-28.205h16.078q0-3.683-1.796-6.018-1.707-2.426-5.66-2.426-3.053 0-5.479 2.156-2.425 2.066-3.143 6.288z"></path>
        </g>
        <g aria-label="Library" fill="#a53995" stroke-width="3.368">
          <path d="M236.48 168.68v-58.925h7.455v52.547h25.78v6.378zM279.42 168.68v-43.655h7.366v43.655zm3.773-52.637q-2.156 0-3.593-1.258-1.348-1.347-1.348-3.593 0-2.155 1.348-3.503 1.437-1.347 3.593-1.347 2.155 0 3.503 1.347 1.437 1.348 1.437 3.503 0 2.246-1.437 3.593-1.348 1.258-3.503 1.258zM320.82 169.76q-3.054 0-6.378-1.437-3.233-1.527-6.108-4.132h-.27l-.628 4.491h-5.928v-63.955h7.365v17.426l-.18 7.905q2.965-2.605 6.468-4.312 3.593-1.796 7.186-1.796 8.533 0 12.935 6.018 4.401 6.018 4.401 16.168 0 7.455-2.694 12.755-2.605 5.3-6.917 8.084-4.222 2.785-9.252 2.785zm-1.258-6.198q5.39 0 8.893-4.58 3.593-4.672 3.593-12.756 0-7.186-2.695-11.587-2.605-4.491-8.803-4.491-2.784 0-5.659 1.527-2.874 1.527-6.018 4.401v22.905q2.875 2.515 5.66 3.593 2.874.988 5.03.988zM351.19 168.68v-43.655h6.108l.629 7.905h.27q2.245-4.132 5.479-6.558 3.233-2.425 6.916-2.425 2.605 0 4.671.898l-1.437 6.468q-1.078-.36-1.976-.54-.899-.179-2.246-.179-2.784 0-5.838 2.246-2.965 2.245-5.21 7.814v28.025zM390.26 169.76q-5.48 0-9.162-3.234-3.593-3.323-3.593-9.162 0-7.186 6.377-10.959 6.468-3.862 20.39-5.39 0-2.784-.808-5.299-.719-2.515-2.695-4.042-1.886-1.617-5.479-1.617-3.773 0-7.096 1.437-3.324 1.438-5.928 3.234l-2.875-5.12q3.054-1.976 7.456-3.773 4.49-1.886 9.7-1.886 7.995 0 11.588 4.94 3.593 4.851 3.593 13.026v26.768h-6.108l-.63-5.21h-.269q-3.054 2.515-6.736 4.401-3.593 1.886-7.725 1.886zm2.156-5.928q3.144 0 5.928-1.527 2.785-1.527 5.929-4.312v-12.126q-10.87 1.347-15.27 4.042-4.312 2.695-4.312 6.917 0 3.682 2.246 5.39 2.245 1.616 5.479 1.616zM425.47 168.68v-43.655h6.108l.629 7.905h.27q2.245-4.132 5.479-6.558 3.233-2.425 6.916-2.425 2.605 0 4.671.898l-1.437 6.468q-1.078-.36-1.976-.54-.898-.179-2.246-.179-2.784 0-5.838 2.246-2.965 2.245-5.21 7.814v28.025zM459.6 187.45q-1.437 0-2.785-.27-1.257-.269-2.335-.628l1.437-5.839q.719.18 1.617.36.898.269 1.707.269 3.683 0 6.108-2.695 2.425-2.605 3.772-6.647l.988-3.233-17.516-43.745h7.636l8.892 24.163q.988 2.784 2.066 6.018 1.168 3.233 2.156 6.287h.36q.987-2.964 1.886-6.197.898-3.234 1.796-6.109l7.815-24.163h7.186l-16.438 47.248q-1.527 4.312-3.683 7.725-2.066 3.414-5.21 5.39-3.054 2.066-7.455 2.066z"></path>
        </g>
        <g aria-label="Trusted evidence." fill="#1f3c73" stroke-width="3.368">
          <path d="M710.25 61.723V30.141h-10.671v-3.773h25.869v3.773h-10.671v31.582zM728.9 61.723V35.53h3.665l.377 4.743h.162q1.347-2.48 3.287-3.935t4.15-1.455q1.563 0 2.803.54l-.863 3.88q-.646-.216-1.185-.324-.54-.108-1.348-.108-1.67 0-3.503 1.348-1.778 1.347-3.126 4.689v16.815zM755.25 62.37q-4.15 0-6.09-2.587-1.94-2.64-1.94-7.653v-16.6h4.473v16.007q0 3.665 1.132 5.336 1.185 1.67 3.772 1.67 2.048 0 3.611-1.024 1.617-1.078 3.45-3.395V35.53h4.42v26.193h-3.666l-.377-4.096h-.162q-1.832 2.156-3.88 3.45-2.048 1.293-4.743 1.293zM783.76 62.37q-2.803 0-5.336-1.024-2.533-1.078-4.419-2.587l2.21-2.964q1.724 1.347 3.557 2.263 1.832.863 4.15.863 2.587 0 3.88-1.186 1.294-1.24 1.294-2.91 0-1.348-.917-2.264-.862-.916-2.263-1.509-1.348-.647-2.803-1.186-1.832-.7-3.61-1.562-1.78-.917-2.911-2.318-1.132-1.455-1.132-3.665 0-3.18 2.372-5.281 2.425-2.156 6.683-2.156 2.425 0 4.527.862t3.61 2.102l-2.155 2.802q-1.347-1.024-2.803-1.67-1.455-.647-3.18-.647-2.479 0-3.664 1.132-1.132 1.132-1.132 2.64 0 1.24.809 2.049.808.754 2.101 1.347 1.294.539 2.749 1.132 1.886.7 3.719 1.617 1.832.862 3.018 2.371 1.24 1.455 1.24 3.934 0 2.102-1.132 3.88-1.078 1.78-3.234 2.857-2.102 1.078-5.228 1.078zM806.67 62.37q-4.204 0-5.875-2.425-1.616-2.426-1.616-6.306V39.141h-3.88V35.8l4.095-.27.54-7.33h3.718v7.33h7.06v3.61h-7.06v14.553q0 2.425.862 3.773.916 1.293 3.18 1.293.7 0 1.509-.216l1.455-.485.863 3.342q-1.078.377-2.372.647-1.24.323-2.479.323zM826.5 62.37q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743-1.67-3.071-1.67-7.33 0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.658-1.67 5.013 0 7.707 3.341 2.749 3.342 2.749 8.947 0 .7-.054 1.401 0 .647-.108 1.132h-17.677q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.616-.593 3.072-1.509l1.562 2.91q-1.67 1.078-3.826 1.887-2.102.808-4.797.808zm-8.246-15.845h14.013q0-3.988-1.725-6.036-1.67-2.102-4.742-2.102-2.749 0-4.958 2.156-2.156 2.102-2.587 5.982zM851.56 62.37q-4.904 0-7.869-3.557-2.964-3.61-2.964-10.132 0-4.258 1.563-7.33 1.617-3.126 4.204-4.796 2.64-1.671 5.605-1.671 2.264 0 3.934.808 1.671.809 3.396 2.21l-.216-4.473V23.35h4.473v38.373h-3.664l-.378-3.072h-.161q-1.51 1.509-3.557 2.64-2.048 1.079-4.366 1.079zm.97-3.719q3.45 0 6.683-3.61V41.35q-1.67-1.509-3.234-2.102-1.509-.646-3.126-.646-2.101 0-3.826 1.293-1.67 1.24-2.695 3.503-1.024 2.21-1.024 5.228 0 4.69 1.886 7.384 1.887 2.64 5.336 2.64zM893.92 62.37q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743t-1.67-7.33q0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.659-1.67 5.012 0 7.706 3.341 2.75 3.342 2.75 8.947 0 .7-.055 1.401 0 .647-.108 1.132h-17.677q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.617-.593 3.072-1.509l1.563 2.91q-1.671 1.078-3.827 1.887-2.102.808-4.796.808zm-8.246-15.845h14.013q0-3.988-1.725-6.036-1.67-2.102-4.742-2.102-2.749 0-4.959 2.156-2.155 2.102-2.587 5.982zM915.97 61.723l-9.432-26.193h4.581l4.959 14.875 1.185 3.88q.647 1.94 1.24 3.827h.216q.592-1.886 1.185-3.827.647-1.94 1.186-3.88l4.958-14.875h4.366l-9.27 26.193zM935.48 61.723V35.53h4.42v26.193zm2.264-31.582q-1.294 0-2.156-.755-.809-.808-.809-2.155 0-1.294.809-2.102.862-.809 2.156-.809 1.293 0 2.101.809.863.808.863 2.102 0 1.347-.862 2.155-.809.755-2.102.755zM957.68 62.37q-4.904 0-7.869-3.557-2.964-3.61-2.964-10.132 0-4.258 1.563-7.33 1.617-3.126 4.204-4.796 2.64-1.671 5.605-1.671 2.264 0 3.934.808 1.671.809 3.396 2.21l-.216-4.473V23.35h4.473v38.373h-3.664l-.378-3.072h-.161q-1.51 1.509-3.557 2.64-2.048 1.079-4.366 1.079zm.97-3.719q3.45 0 6.683-3.61V41.35q-1.67-1.509-3.234-2.102-1.509-.646-3.126-.646-2.101 0-3.826 1.293-1.67 1.24-2.695 3.503-1.024 2.21-1.024 5.228 0 4.69 1.887 7.384 1.886 2.64 5.335 2.64zM989.26 62.37q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743t-1.67-7.33q0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.658-1.67 5.013 0 7.707 3.341 2.749 3.342 2.749 8.947 0 .7-.054 1.401 0 .647-.108 1.132h-17.677q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.616-.593 3.072-1.509l1.563 2.91q-1.671 1.078-3.827 1.887-2.102.808-4.797.808zm-8.246-15.845h14.013q0-3.988-1.725-6.036-1.67-2.102-4.742-2.102-2.749 0-4.958 2.156-2.156 2.102-2.587 5.982zM1005.4 61.723V35.53h3.665l.377 3.773h.162q1.886-1.887 3.988-3.126 2.102-1.294 4.797-1.294 4.15 0 6.036 2.641 1.94 2.587 1.94 7.6v16.6h-4.42V45.715q0-3.665-1.185-5.335t-3.773-1.671q-1.994 0-3.61 1.024-1.563 1.024-3.558 3.018v18.971zM1045.2 62.37q-3.45 0-6.252-1.617t-4.42-4.689q-1.616-3.072-1.616-7.383 0-4.42 1.725-7.492 1.778-3.072 4.635-4.688 2.91-1.617 6.251-1.617 2.587 0 4.42.916 1.886.916 3.233 2.156l-2.263 2.91q-1.132-1.024-2.425-1.67-1.24-.647-2.803-.647-2.371 0-4.258 1.293-1.832 1.24-2.91 3.557-1.024 2.264-1.024 5.282 0 4.473 2.21 7.276 2.263 2.748 5.874 2.748 1.833 0 3.396-.754 1.563-.809 2.748-1.887l1.94 2.965q-1.778 1.563-3.934 2.479-2.156.862-4.527.862zM1068.9 62.37q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743-1.67-3.071-1.67-7.33 0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.659-1.67 5.012 0 7.707 3.341 2.748 3.342 2.748 8.947 0 .7-.054 1.401 0 .647-.108 1.132h-17.678q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.617-.593 3.072-1.509l1.563 2.91q-1.671 1.078-3.827 1.887-2.102.808-4.797.808zm-8.246-15.845h14.013q0-3.988-1.724-6.036-1.671-2.102-4.743-2.102-2.749 0-4.958 2.156-2.156 2.102-2.587 5.982zM1087.4 62.37q-1.347 0-2.317-.916-.917-.97-.917-2.426 0-1.562.917-2.479.97-.97 2.317-.97 1.294 0 2.21.97.97.916.97 2.48 0 1.455-.97 2.425-.916.916-2.21.916z"></path>
        </g>
        <g aria-label="Informed decisions." fill="#1f3c73" stroke-width="3.368">
          <path d="M699.58 124.7V89.345h4.473V124.7zM713.32 124.7V98.507h3.665l.377 3.773h.162q1.886-1.887 3.988-3.126 2.102-1.294 4.797-1.294 4.15 0 6.036 2.641 1.94 2.587 1.94 7.6v16.6h-4.42v-16.008q0-3.665-1.185-5.335-1.186-1.671-3.773-1.671-1.994 0-3.61 1.024-1.564 1.024-3.558 3.018V124.7zM743.56 124.7v-22.582h-3.557v-3.341l3.557-.27v-4.15q0-3.988 1.832-6.306 1.887-2.371 5.821-2.371 1.24 0 2.371.27 1.132.215 1.995.592l-.97 3.396q-1.456-.647-2.965-.647-3.665 0-3.665 5.066v4.15h5.552v3.61h-5.552V124.7zM768.19 125.35q-3.18 0-5.982-1.617-2.749-1.617-4.474-4.689-1.67-3.072-1.67-7.383 0-4.42 1.67-7.492 1.725-3.072 4.474-4.688 2.802-1.617 5.982-1.617 3.234 0 5.982 1.617 2.749 1.616 4.42 4.688 1.724 3.072 1.724 7.492 0 4.311-1.724 7.383-1.671 3.072-4.42 4.69t-5.982 1.616zm0-3.665q3.395 0 5.443-2.748 2.102-2.803 2.102-7.276 0-4.527-2.102-7.33-2.048-2.802-5.443-2.802-3.341 0-5.443 2.802t-2.102 7.33q0 4.473 2.102 7.276 2.102 2.748 5.443 2.748zM787.21 124.7V98.507h3.665l.377 4.743h.162q1.347-2.48 3.287-3.935t4.15-1.455q1.563 0 2.803.54l-.863 3.88q-.646-.216-1.185-.324-.54-.108-1.348-.108-1.67 0-3.503 1.348-1.778 1.347-3.126 4.689V124.7zM805.91 124.7V98.507h3.665l.377 3.773h.162q1.724-1.887 3.772-3.126 2.048-1.294 4.366-1.294 3.018 0 4.689 1.348 1.724 1.293 2.533 3.664 2.048-2.21 4.15-3.61 2.101-1.402 4.473-1.402 4.042 0 5.982 2.641 1.994 2.587 1.994 7.6v16.6h-4.42v-16.008q0-3.665-1.185-5.335-1.186-1.671-3.665-1.671-2.91 0-6.575 4.042V124.7h-4.42v-16.007q0-3.665-1.185-5.336-1.186-1.67-3.719-1.67-2.91 0-6.575 4.042v18.97zM861.21 125.35q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743-1.67-3.071-1.67-7.33 0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.658-1.67 5.013 0 7.707 3.341 2.749 3.342 2.749 8.947 0 .7-.054 1.401 0 .647-.108 1.132h-17.677q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.616-.593 3.072-1.509l1.562 2.91q-1.67 1.078-3.826 1.887-2.102.808-4.797.808zm-8.246-15.845h14.013q0-3.988-1.724-6.036-1.671-2.102-4.743-2.102-2.749 0-4.958 2.156-2.156 2.102-2.587 5.982zM886.27 125.35q-4.904 0-7.869-3.557-2.964-3.61-2.964-10.132 0-4.258 1.563-7.33 1.617-3.126 4.204-4.796 2.64-1.671 5.605-1.671 2.264 0 3.934.808 1.671.809 3.396 2.21l-.216-4.473V86.33h4.473v38.373h-3.664l-.378-3.072h-.161q-1.51 1.509-3.557 2.64-2.048 1.079-4.366 1.079zm.97-3.719q3.45 0 6.683-3.61v-13.69q-1.67-1.509-3.234-2.102-1.509-.646-3.126-.646-2.101 0-3.826 1.293-1.67 1.24-2.695 3.503-1.024 2.21-1.024 5.228 0 4.689 1.886 7.384 1.887 2.64 5.336 2.64zM926.96 125.35q-4.904 0-7.869-3.557-2.964-3.61-2.964-10.132 0-4.258 1.563-7.33 1.617-3.126 4.204-4.796 2.64-1.671 5.605-1.671 2.264 0 3.934.808 1.671.809 3.396 2.21l-.216-4.473V86.33h4.473v38.373h-3.664l-.378-3.072h-.161q-1.51 1.509-3.557 2.64-2.048 1.079-4.366 1.079zm.97-3.719q3.45 0 6.683-3.61v-13.69q-1.67-1.509-3.234-2.102-1.509-.646-3.125-.646-2.102 0-3.827 1.293-1.67 1.24-2.695 3.503-1.024 2.21-1.024 5.228 0 4.689 1.887 7.384 1.886 2.64 5.335 2.64zM958.54 125.35q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743t-1.67-7.33q0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.658-1.67 5.013 0 7.707 3.341 2.749 3.342 2.749 8.947 0 .7-.054 1.401 0 .647-.108 1.132h-17.677q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.616-.593 3.072-1.509l1.563 2.91q-1.671 1.078-3.827 1.887-2.102.808-4.797.808zm-8.246-15.845h14.013q0-3.988-1.725-6.036-1.67-2.102-4.742-2.102-2.749 0-4.959 2.156-2.155 2.102-2.587 5.982zM985.01 125.35q-3.45 0-6.252-1.617-2.802-1.617-4.42-4.689-1.616-3.072-1.616-7.383 0-4.42 1.725-7.492 1.778-3.072 4.635-4.688 2.91-1.617 6.251-1.617 2.587 0 4.42.916 1.886.916 3.233 2.156l-2.263 2.91q-1.132-1.024-2.425-1.67-1.24-.647-2.803-.647-2.371 0-4.258 1.293-1.832 1.24-2.91 3.557-1.024 2.264-1.024 5.282 0 4.473 2.21 7.276 2.263 2.748 5.874 2.748 1.833 0 3.396-.754 1.563-.809 2.748-1.887l1.94 2.965q-1.778 1.563-3.934 2.479-2.156.862-4.527.862zM999.23 124.7V98.507h4.42V124.7zm2.264-31.582q-1.294 0-2.156-.755-.809-.808-.809-2.155 0-1.294.809-2.102.862-.809 2.156-.809 1.293 0 2.101.809.863.808.863 2.102 0 1.347-.862 2.155-.809.755-2.102.755zM1019.3 125.35q-2.803 0-5.336-1.024-2.533-1.078-4.419-2.587l2.21-2.964q1.724 1.347 3.557 2.263 1.832.863 4.15.863 2.587 0 3.88-1.186 1.293-1.24 1.293-2.91 0-1.348-.916-2.264-.862-.916-2.263-1.509-1.348-.647-2.803-1.185-1.832-.701-3.61-1.563-1.78-.917-2.911-2.318-1.132-1.455-1.132-3.665 0-3.18 2.371-5.281 2.426-2.156 6.683-2.156 2.426 0 4.528.862 2.101.862 3.61 2.102l-2.155 2.803q-1.348-1.024-2.803-1.671-1.455-.647-3.18-.647-2.479 0-3.664 1.132-1.132 1.132-1.132 2.64 0 1.24.808 2.049.809.754 2.102 1.347 1.294.539 2.749 1.132 1.886.7 3.718 1.617 1.833.862 3.019 2.371 1.24 1.455 1.24 3.934 0 2.102-1.133 3.88-1.078 1.78-3.233 2.857-2.102 1.078-5.228 1.078zM1035.1 124.7V98.507h4.42V124.7zm2.264-31.582q-1.294 0-2.156-.755-.809-.808-.809-2.155 0-1.294.809-2.102.862-.809 2.156-.809t2.101.809q.863.808.863 2.102 0 1.347-.863 2.155-.808.755-2.101.755zM1058.5 125.35q-3.18 0-5.982-1.617-2.749-1.617-4.474-4.689-1.67-3.072-1.67-7.383 0-4.42 1.67-7.492 1.725-3.072 4.474-4.688 2.802-1.617 5.982-1.617 3.234 0 5.982 1.617 2.749 1.616 4.42 4.688 1.724 3.072 1.724 7.492 0 4.311-1.724 7.383-1.671 3.072-4.42 4.69-2.748 1.616-5.982 1.616zm0-3.665q3.395 0 5.443-2.748 2.102-2.803 2.102-7.276 0-4.527-2.102-7.33-2.048-2.802-5.443-2.802-3.341 0-5.443 2.802t-2.102 7.33q0 4.473 2.102 7.276 2.101 2.748 5.443 2.748zM1077.5 124.7V98.507h3.665l.377 3.773h.162q1.886-1.887 3.988-3.126 2.102-1.294 4.797-1.294 4.15 0 6.036 2.641 1.94 2.587 1.94 7.6v16.6h-4.42v-16.008q0-3.665-1.185-5.335-1.186-1.671-3.773-1.671-1.994 0-3.61 1.024-1.564 1.024-3.558 3.018V124.7zM1113.9 125.35q-2.803 0-5.336-1.024-2.533-1.078-4.419-2.587l2.21-2.964q1.724 1.347 3.557 2.263 1.832.863 4.15.863 2.587 0 3.88-1.186 1.293-1.24 1.293-2.91 0-1.348-.916-2.264-.862-.916-2.263-1.509-1.348-.647-2.803-1.185-1.832-.701-3.61-1.563-1.78-.917-2.911-2.318-1.132-1.455-1.132-3.665 0-3.18 2.372-5.281 2.425-2.156 6.683-2.156 2.425 0 4.527.862 2.102.862 3.61 2.102l-2.155 2.803q-1.348-1.024-2.803-1.671-1.455-.647-3.18-.647-2.479 0-3.664 1.132-1.132 1.132-1.132 2.64 0 1.24.808 2.049.809.754 2.102 1.347 1.294.539 2.749 1.132 1.886.7 3.718 1.617 1.833.862 3.019 2.371 1.24 1.455 1.24 3.934 0 2.102-1.133 3.88-1.078 1.78-3.233 2.857-2.102 1.078-5.228 1.078zM1131.9 125.35q-1.347 0-2.317-.916-.917-.97-.917-2.426 0-1.562.917-2.479.97-.97 2.317-.97 1.294 0 2.21.97.97.916.97 2.48 0 1.455-.97 2.425-.916.916-2.21.916z"></path>
        </g>
        <g aria-label="Better health." fill="#a53995" stroke-width="3.368">
          <path d="M699.58 187.95v-35.355h10.509q3.61 0 6.306.862 2.748.863 4.257 2.749 1.563 1.886 1.563 5.012 0 2.64-1.347 4.797-1.294 2.102-3.827 2.91v.216q3.18.592 5.174 2.694 2.048 2.102 2.048 5.767 0 3.45-1.724 5.767-1.671 2.317-4.69 3.449-3.017 1.132-7.005 1.132zm4.473-20.318h5.228q4.527 0 6.521-1.563 1.994-1.563 1.994-4.258 0-3.072-2.101-4.365-2.048-1.294-6.198-1.294h-5.444zm0 16.761h6.144q4.581 0 7.114-1.67 2.533-1.725 2.533-5.282 0-3.288-2.533-4.797-2.479-1.563-7.114-1.563h-6.144zM741.46 188.6q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743-1.67-3.072-1.67-7.33 0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.659-1.67 5.012 0 7.706 3.341 2.75 3.342 2.75 8.947 0 .7-.055 1.401 0 .647-.108 1.132h-17.677q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.617-.593 3.072-1.509l1.563 2.91q-1.671 1.078-3.827 1.887-2.102.808-4.796.808zm-8.246-15.845h14.013q0-3.988-1.724-6.036-1.671-2.102-4.743-2.102-2.749 0-4.958 2.156-2.156 2.102-2.587 5.982zM765.28 188.6q-4.204 0-5.875-2.425-1.616-2.426-1.616-6.306v-14.498h-3.88v-3.341l4.095-.27.54-7.33h3.718v7.33h7.06v3.611h-7.06v14.552q0 2.425.862 3.773.916 1.293 3.18 1.293.7 0 1.51-.215l1.454-.486.863 3.342q-1.078.377-2.372.647-1.24.323-2.479.323zM782.42 188.6q-4.204 0-5.875-2.425-1.616-2.426-1.616-6.306v-14.498h-3.88v-3.341l4.095-.27.54-7.33h3.718v7.33h7.06v3.611h-7.06v14.552q0 2.425.862 3.773.916 1.293 3.18 1.293.7 0 1.51-.215l1.454-.486.863 3.342q-1.078.377-2.372.647-1.24.323-2.479.323zM802.25 188.6q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743-1.67-3.072-1.67-7.33 0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.658-1.67 5.013 0 7.707 3.341 2.749 3.342 2.749 8.947 0 .7-.054 1.401 0 .647-.108 1.132h-17.677q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.616-.593 3.072-1.509l1.562 2.91q-1.67 1.078-3.826 1.887-2.102.808-4.797.808zm-8.246-15.845h14.013q0-3.988-1.725-6.036-1.67-2.102-4.742-2.102-2.749 0-4.958 2.156-2.156 2.102-2.587 5.982zM818.36 187.95v-26.193h3.665l.377 4.743h.162q1.347-2.48 3.287-3.935t4.15-1.455q1.563 0 2.803.54l-.863 3.88q-.646-.216-1.185-.324t-1.348-.108q-1.67 0-3.503 1.348-1.778 1.347-3.126 4.689v16.815zM847.84 187.95v-38.373h4.42v10.456l-.162 5.39q1.886-1.779 3.934-3.019 2.102-1.293 4.797-1.293 4.15 0 6.036 2.64 1.94 2.588 1.94 7.6v16.6h-4.42v-16.007q0-3.665-1.185-5.336-1.186-1.67-3.773-1.67-1.994 0-3.61 1.024-1.564 1.024-3.558 3.018v18.97zM887.78 188.6q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743-1.67-3.072-1.67-7.33 0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.659-1.67 5.012 0 7.706 3.341 2.75 3.342 2.75 8.947 0 .7-.055 1.401 0 .647-.108 1.132h-17.677q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.617-.593 3.072-1.509l1.563 2.91q-1.671 1.078-3.827 1.887-2.102.808-4.796.808zm-8.246-15.845h14.013q0-3.988-1.725-6.036-1.67-2.102-4.742-2.102-2.749 0-4.959 2.156-2.155 2.102-2.586 5.982zM909.18 188.6q-3.288 0-5.497-1.94-2.156-1.994-2.156-5.498 0-4.311 3.826-6.575 3.88-2.317 12.234-3.233 0-1.671-.485-3.18-.43-1.51-1.616-2.426-1.132-.97-3.288-.97-2.264 0-4.258.863-1.994.862-3.557 1.94l-1.724-3.072q1.832-1.186 4.473-2.264 2.695-1.131 5.82-1.131 4.797 0 6.953 2.964 2.156 2.91 2.156 7.814v16.061h-3.665l-.377-3.125h-.162q-1.832 1.509-4.042 2.64-2.156 1.132-4.635 1.132zm1.294-3.557q1.886 0 3.556-.916 1.671-.916 3.557-2.587v-7.276q-6.52.808-9.162 2.425-2.587 1.617-2.587 4.15 0 2.21 1.348 3.234 1.347.97 3.287.97zM934.99 188.6q-2.48 0-3.61-1.509-1.079-1.563-1.079-4.42v-33.09h4.42v33.415q0 1.024.377 1.509.377.43.862.43h.377q.216-.053.593-.107l.593 3.341q-.431.216-1.024.324-.593.108-1.509.108zM952.29 188.6q-4.204 0-5.875-2.425-1.616-2.426-1.616-6.306v-14.498h-3.88v-3.341l4.095-.27.54-7.33h3.718v7.33h7.06v3.611h-7.06v14.552q0 2.425.862 3.773.916 1.293 3.18 1.293.7 0 1.51-.215l1.454-.486.863 3.342q-1.078.377-2.372.647-1.24.323-2.479.323zM962.26 187.95v-38.373h4.42v10.456l-.162 5.39q1.886-1.779 3.934-3.019 2.102-1.293 4.797-1.293 4.15 0 6.036 2.64 1.94 2.588 1.94 7.6v16.6h-4.42v-16.007q0-3.665-1.185-5.336-1.186-1.67-3.773-1.67-1.994 0-3.61 1.024-1.564 1.024-3.558 3.018v18.97zM993.9 188.6q-1.347 0-2.317-.916-.917-.97-.917-2.426 0-1.563.916-2.479.97-.97 2.318-.97 1.294 0 2.21.97.97.917.97 2.48 0 1.455-.97 2.425-.917.916-2.21.916z"></path>
        </g>
      </svg>
    </div>
    <h1>Supplementary material 26 to: Daily iron supplementation for prevention or treatment of iron deficiency anaemia in infants, children, and adolescents</h1>
    <p>
      <span class="byline">Rajagopalan K, Hackl L, Pe&ntilde;a-Rosas JP, Garcia-Casal MN, Rizal M, Mehta NH, Roudik M, Islam S, Trumbull-Kennedy MM, Khondakar NR, Franco JVA, Finkelstein JL, Mehta S</span>
      <br>
      <span class="doi"><a href="https://doi.org/10.1002/14651858.CD013227.pub2">https://doi.org/10.1002/14651858.CD013227.pub2</a></span>
    </p>
    <p>
      <span class="disclaimer">The material in this section has been supplied by the author(s) for publication under a Licence for Publication and the author(s) are solely responsible for the material. Cochrane has reviewed this material, but Cochrane has not copyedited, formatted or proofread. Cochrane accordingly gives no representations or warranties of any kind in relation to, and accepts no liability for any reliance on or use of, such material.</span>
    </p>
    <div id="backToTop">
      <a href="#top">Back to top</a>
    </div>
    <h1>Description of Interventions_2</h1>
    <p> 
    </p>
    <div>
      <table>
        <tr>
          <th style="vertical-align: top;">
            <p>Item</p>
          </th><th style="vertical-align: top;">
            <p>Study ID</p>
          </th>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td style="vertical-align: top;">
            <p>Parkin 2021</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name<br>  
            </p>
          </td><td style="vertical-align: top;">
            <p>Iron and diet versus diet only</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>children 1 to 3 yr with non-anaemic ID</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>"It is unknown whether an age-appropriate diet of iron-rich foods and optimal feeding practices may be effective in treating nonane-mic iron deﬁciency. [<a href="#433424061920088765">1</a>]"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td style="vertical-align: top;">
            <p>"All parents received an information sheet regarding possible adverse effects of oral iron such as constipation and black stools, which were described as reversible and nonharmful."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>"Child and family characteristics were collected using a standardized questionnaire and the child&rsquo;s anthropometric measurements were obtained. Blood samples were obtained and analyzed within 4-6 hours. Hemoglobin was analyzed on the Sysmex XN-9000 Hematology Analyzer (Kobe, Japan); serum ferritin and CRP were analyzed on the Roche platform...</p>
            <p>The primary outcome was obtained at the 4-month visit using the Early Learning Composite (ELC) from the Mullen Scales of Early Learning (MSEL). [<a href="#433424035792196284">2</a>] The MSEL measures 5 developmental skills: gross motor and 4 cognitive skills (ﬁne motor, visual reception, receptive language, expressive language). The 4 cognitive skills are summarized and converted into age-adjusted normalized ELC scores, with a mean of 100 and SD of 15. ELC test properties include test&ndash;retest reliability 0.84, inter-rater reliability 0.98-0.99, and construct validity 0.70 (compared with the Bayley Scales of Infant Development [BSID], Mental Development Index).[<a href="#433424035792196284">2</a>] The same trained psychometrist and psychologist completed all assessments and were blinded to laboratory results and group allocation.<br> Secondary outcomes included the ELC at 12 months, scores for the 5 individual MSEL developmental skills, serum ferritin and hemoglobin at 4 and 12 months. Adherence and adverse effects were measured using a standardized, parent-completed questionnaire at the 4-month visit, corresponding to the completion of the intervention."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>parents provided supplements</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>"receive either liquid ferrous sulfate... or liquid placebo... in 2 divided doses daily by mouth for 4 months."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>home-based supplementation, testing occurred at primary care practices</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much<br>  
            </p>
          </td><td style="vertical-align: top;">
            <p>"liquid ferrous sulfate (6 mg elemental iron/kg/d, Fer-In-Sol, supplied by Mead Johnson Nutrition) or liquid placebo (equivalent vol-ume) in 2 divided doses daily by mouth for 4 months"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring<br>  
            </p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity </p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td style="vertical-align: top;">
            <p>In a typical week, 32.2 % of participants in the ferrous sulphate group were reported to have received the study drug 4 to 7 d/wk and in the placebo group 55.2 %.</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p> 
            </p>
          </td><td style="vertical-align: top;">
            <p> 
            </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>Reynolds 2020</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name<br>  
            </p>
          </td><td style="vertical-align: top;">
            <p>The Effect of Ferrous Sulphate to Treat Insomnia in Children With Autism Spectrum Disorders </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>children 2 to 10 yr of age with autism spectrum disorders and low normal ferritin levels<br>  
            </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>"Although some clinicians empirically treat children with ASD [autism spectrum disorder], insomnia, and ferritin less than 50 ng/mL with oral iron, evidence of the efficacy of iron supplementation in treating insomnia is limited to one open-label study in children with ASD."[<a href="#422043635180836938">3</a>]</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td style="vertical-align: top;">
            <p>"Parents were educated on prevention of overdose." </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>"Children who met initial inclusion criteria underwent laboratory evaluation of serum ferritin and C-reactive protein (CRP) to further determine eligibility. A ferritin level between 17 and 49 ng/mL was considered inclusionary based on normal values for the central laboratory at the University of Colorado. Because ferritin is an acute-phase reactant, CRP was obtained to ensure that ferritin was not falsely elevated due to inflammation. Phlebotomy was postponed if a child had a fever within the previous week. If the CRP was elevated, ferritin and CRP were repeated once the inflammatory process had resolved. Hematocrit, hemoglobin, and mean cell volume were also completed locally if not done within 60 days of study start. Children with anemia were excluded...Subjects were monitored for adverse events one week after the baseline visit, and every two weeks subsequently by phone or during monthly clinic visits... In addition to asking about any current illness, the Hague Side Effect Profile was used to capture adverse events. After three months, repeat serum ferritin and CRP were obtained, along with actigraphy, sleep diary, CSHQ [Children's Sleep Habits Questionnaire], Sleep CGI [Clinical Global Impression], and behavioral measures" </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>"Parents were instructed to give the study liquid" </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>individual<br>  
            </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>home-based supplementation, testing occurred at one of four sites: University of Colorado Denver, Vanderbilt University Medical Center, University of Rochester MedicalCenter, and University of Toronto</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much<br>  
            </p>
          </td><td style="vertical-align: top;">
            <p>"Liquid ferrous sulfate (Fer-in-sol, provided by Mead Johnson)was used under the US Food and Drug AdministrationIND #113508.</p>
            <p>A placebo liquid of similar taste, consistency, and color was prepared by the local investigational drug services department at each institution. Parents were instructed to give the study liquid at least 30 minutes before a meal or two hours after a meal."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring<br>  
            </p>
          </td><td style="vertical-align: top;">
            <p>"If the child needed to take the study liquid with a liquid other than water, the liquid was to contain vitamin C." </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;<br>  
            </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity </p>
          </td><td style="vertical-align: top;">
            <p>"Compliance was measured based on volume of liquid dispensed versus volume returned."<br>  
            </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"Compliance rates were good for subjects taking iron, ranging from 83% to 107% (mean ˜95%) based on volume dispensed minus volume returned. Compliance was more variable for subjects taking placebo, ranging from 57% to 106% (mean ˜84%). Compliance was based on volume returned, therefore, it is possible that some liquid was spilled making compliance appear to be greater than 100%." </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>Bora 2019</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>Iron supplementation in neonates </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>term infants of mothers with and without anaemia</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>to investigate whether beginning iron supplementation from the second day after birth improves the iron status (Hb, serum ferritin) and motor development of infants at 6&thinsp;months in a population at high risk of early iron deficiency due to maternal iron deficiency in pregnancy...In a developing country with a population at high risk of iron deficiency, waiting to begin iron supplementation until 4 months is potentially too late for preventing early iron deficiency and associated risk of neurodevelopmental deficits."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>Infants in the iron-supplementation group received ferrous ascorbate (elemental iron, 10 mg/mL) at a dose of 2 mg/kg/day of elemental iron beginning at 36 hours after birth until 6 months of age, Infants in the no iron-supplementation group did not receive additional iron beyond that available in the breast milk. </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"Mothers were counseled on the benefits of breastfeeding and establishment of successful breastfeeding was ensured prior to discharge... At the 6-month visit, 4 mL of blood was collected for determining Hb and serum ferritin. Motor assessment was performed using [sic] Amiel Tison and Simplified Dubowitz method which includes eight items". [<a href="#421543703008924230">4</a>, <a href="#422086376837873942">5</a>]</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>supplementation was home-based upon discharge, follow-up visits were conducted individually</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"Infants were followed in the hospital until discharge and then at 1.5, 2.5, 3.5 and 6.0&thinsp;months on their immunization days. Telephone contact was maintained at least once in between the visits." </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much<br>  
            </p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>Iron supplements and placebos were administered daily at a dose of 2 or 0 mg/kg/day in the iron-supplementation and placebo-supplementation group, respectively.</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>&mdash;<br>  
            </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity<br>  
            </p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"Two hundred  mother-infant dyads  were  enrolled  and  182infants were assessed at follow-up (90% follow-uprate). Data from two neonates were excluded from analysis  because  of  elevated  cord  blood  CRP (&gt;6mg dL<sup> &ndash;1</sup>), resulting in a final sample size of 180 (45 from each of the 4 subgroups)." </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td style="vertical-align: top;">
            <p>Johnstone 2019</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td style="vertical-align: top;">
            <p>Micronutrients for ADHD in Youth (MADDY) Study</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>Children aged 6&ndash;12 years diagnosed with ADHD and at least one impairing symptom of irritability</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>To assess whether a broad-spectrum micronutrient formula benefits ADHD symptoms and irritability in youth, and whether it is safe and tolerable as a non-pharmacological alternative</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td style="vertical-align: top;">
            <p>- Active supplement: Daily Essential Nutrients (36-ingredient micronutrient formula; vitamins, minerals, amino acids, antioxidants)<br> - Placebo: visually identical capsules containing cellulose filler and 0.1 mg riboflavin<br> - Vanilla-scented desiccants used in both groups to mimic smell</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>- 8-week, 3:2 randomized, double-blind, placebo-controlled multicenter trial<br> - Dosing ramp-up: 1 capsule 3&times;/day Day 1&ndash;2, 2 caps 3&times;/day Day 3&ndash;4, 3 caps 3&times;/day thereafter<br> - Option to increase to 4 caps 3&times;/day after Week 4 (for children over 9 years)<br> - Pre- and post-trial assessments: blood and urine tests, anthropometry, CGI-I and CASI-5 (parent, teacher, and clinician ratings)<br> - Adverse events assessed using PAERS</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>Hardy Nutritionals provided capsules; caregivers administered supplements at home; trained study staff performed assessments</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>Individually administered at home by caregivers with food, 3&times; daily</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>3 sites: Oregon Health &amp; Science University, Ohio State University, and University of Lethbridge (Canada)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td style="vertical-align: top;">
            <p>- 9 to 12 capsules per day, taken in 3 divided doses for 8 weeks<br> - Dosage tailored by age (6&ndash;9 years: max 9/day; over 9 years: up to 12/day)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td style="vertical-align: top;">
            <p>Dosing ramped and adjusted based on age and tolerability; option to reduce to 6 capsules/day if needed</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td style="vertical-align: top;">
            <p>n/a</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity </p>
          </td><td style="vertical-align: top;">
            <p>- Randomized sequence created independently<br> - Blinding strictly maintained across participants, caregivers, and staff<br> - Pill counts conducted by blinded research staff at follow-ups<br> - Adherence assessed through capsule return and caregiver report</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td style="vertical-align: top;">
            <p>- High: 93% retention; 74% met per-protocol adherence (&ge;80% of capsules taken)<br> - Blinding preserved; minimal loss to follow-up</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td style="vertical-align: top;">
            <p>Rucklidge 2018</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td style="vertical-align: top;">
            <p>Micronutrient treatment for children with ADHD (Daily Essential Nutrients, DEN)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>Children aged 7&ndash;12 years diagnosed with ADHD (medication-free for &ge;4 weeks)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>To evaluate the efficacy and safety of a broad-spectrum micronutrient formula for improving core ADHD symptoms, emotional regulation, aggression, and overall functioning in children</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td style="vertical-align: top;">
            <p>- Active: Daily Essential Nutrients (DEN): 36 ingredients (13 vitamins, 17 minerals, 4 amino acids)<br> - Placebo: visually identical capsules with cellulose filler + riboflavin (to mimic smell and urine color)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>- 10-week randomized, fully blinded, placebo-controlled parallel-group trial<br> - Participants titrated dose up to 12 capsules/day (target), with possible increase to 15 capsules/day<br> - In-person visits every 2 weeks; clinician, parent, teacher, and child assessments conducted<br> - Blood tests for safety (e.g., liver function, nutrient levels); unused pills collected for adherence check<br> - Measures included: ADHD-RS-IV, CPRS-R:L, SDQ, BRIEF, CGI-I, MYMOP, CMRS-P</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>Caregivers administered supplements; study staff supervised assessments and adherence; formula provided by Hardy Nutritionals</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>Individually taken at home with food and water, 3&times; per day; supervised via study monitoring</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>University of Canterbury, Christchurch, New Zealand</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td style="vertical-align: top;">
            <p>- 10-week duration<br> - Titrated from 3 capsules/day to 12/day (target) in 3 divided doses; increased to 15/day after 4 weeks if no improvement<br> - Average: 11.8 capsules/day (micronutrient group), 11.4 (placebo)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td style="vertical-align: top;">
            <p>Dose adjusted based on clinical response and tolerability (e.g., increase to 15/day after Week 4 if CGI-I &ge;3)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td style="vertical-align: top;">
            <p>n/a</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity </p>
          </td><td style="vertical-align: top;">
            <p>- Participants used a pill box; visits every 2 weeks<br> - Capsule counts and self-reports used to track adherence<br> - Adherence reinforced with reminders and instructions<br> - Placebo mimicked smell and visual appearance of DEN</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td style="vertical-align: top;">
            <p>High:<br> - Self-reported adherence: 95.4% (micronutrients), 93.0% (placebo)<br> - Pill count adherence: 90.5% (micronutrients), 91.5% (placebo)<br> - Retention: 96%; non-adherence (&lt;75% doses) in 5 (micronutrients), 2 (placebo)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td style="vertical-align: top;">
            <p>Nair 2017</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td style="vertical-align: top;">
            <p>Prevention of iron deficiency anaemia in infants </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>4-6-month-old infants without anaemia</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>determine the "effect of iron prophylaxis in term infants from four-to-six months of age in preventing iron deficiency anaemia at one year of age"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td style="vertical-align: top;">
            <p>infants in the intervention group received elemental iron as a syrup with vitamin D3 drops, whereas those in the control group received only vitamin D3 drops</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>"Infants were selected alternatively; first infant came with the eligible criteria put on iron supplementation group, next infant in the non-iron supplement (control) group and so on. Total 44 infants enrolled with 22 in each group. Information about history, examination and anthropometry were entered in proforma. One group was given iron syrup (elemental iron as colloidal iron) at 2 mg/kg/day along with vitamin D3 drops as per IAP recommendation; second group only vitamin D3.</p>
            <p>Both the groups were asked to report every 3 months. They were assessed by clinical examination and growth parameters. During followup, enquiry was made about iron compliance. At the end that is by one year of age, all infants were reassessed and repeated haemoglobin level. If final Hb level was less than 11 g%, detailed evaluation for anaemia, with PCV, MCV, MCH, MCHC, Peripheral Smear, Retic Count, Serum Ferritin and Stool occult blood was also done."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>individual</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>home based ; children attended the well baby clinic in a tertiary hospital</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much<br>  
            </p>
          </td><td style="vertical-align: top;">
            <p>2 mg/kg/day</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity<br>  
            </p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td style="vertical-align: top;">
            <p>Deli 2017</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td style="vertical-align: top;">
            <p>"Iron supplementation effects on redox status following Aseptic Skeletal Muscle Trauma in adults and children" </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>"preadolescent males (10&ndash;12 y)"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>"The present study investigated the age-dependent effect of iron supplementation on possible alterations of redox status after muscle-damaging eccentric exercise."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)<br>  
            </p>
          </td><td style="vertical-align: top;">
            <p>"Subjects were advised, for better absorption, to consume the supplement in the morning on an empty stomach or at least 2 h after breakfast and 2 h before lunch." </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>"bodymass was measured to the nearest 0.05 kg (Beam Balance 710; Seca, Birmingham, United Kingdom) while the subjects were lightly dressed and barefoot. Standing height was measured to the nearest 0.5 cm (Stadiometer 208; Seca). Percentage body fat was calculated from 7 skinfold-thickness measures (average of 2 measurements of each site) by using a Harpenden caliper (John Bull, St Albans, United Kingdom). The Siri skinfold-thickness equation was used to calculate bodyfat. Biological age of children was assessed by self-estimation of the subjects of Tanner&rsquo;s sexual maturation stages through drawings that depicted the different Tanner stages of sexual maturity and accompanied by the appropriate guidelines, as previously described ([<a href="#422243992020739369">6</a>], Deli 2017)...The eccentric exercise protocol was performed on an isokinetic dynamometer (Cybex, Ronkonkoma, NY). Subjects performed the exercise during the first cycle with one leg, after being randomly allocated to one of the two experimental conditions (supplement or placebo) that lasted for 3 weeks prior to and another 96 h after the exercise. Following a 4-week washout period, subjects performed the exercise during the second cycle with the contralateral leg under the secondcondition. The leg that was used in each cycle was also randomly assigned. Blood samples were collected at baseline, after 2 weeks of supplementation (preexercise), and 72 h following exercise...<br> Blood samples (10 mL) were drawn from a forearm vein and plasma and red bloodcells lysate were collected as previously described [46]. A blood aliquot (1.5 mL) was collected into ethylenediaminettraacetic acid (EDTA) tubes for the estimation of hematological parameters. For serum, blood was collected into tubes containing coagulation agent and after staying for 20 min to clot, it was centrifuged at 1370 &times; g for 10 min at 4∘C, and serum was collected. Plasma, erythrocytes lysate, and serum were stored in multiple aliquots at&minus;80∘C and thawed only once before the analyses....Iron concentration and total iron binding capacity (TIBC) were estimated in a Clinical Chemistry Analyzer Z 1145 (Zafiropoulos Diagnostica, Athens, Greece) with commercially available kits (Zafiropoulos, Athens, Greece).Each sample was analyzed in duplicate. Transferrin saturation (TS) was calculated through the ratio of iron concentration and TIBC (total iron binding capacity; TS = iron concentration/TIBC&times;100). For the determination of serum ferritin, an immunoenzymometric assay kit based on sandwich ELISA was used (Accubind&reg;, Monobind Inc., USA)." </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>supplementation was home-based, but it is not clearly stated whether the exercise protocol was performed individually or in groups</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td style="vertical-align: top;">
            <p>"daily either 37 mg of elemental iron or placebo for 3 weeks prior to and up to 72 h after an acute eccentric exercise bout&hellip;crossover"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;<br>  
            </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity</p>
          </td><td style="vertical-align: top;">
            <p>"each individual received the supplement prepacked in daily doses labeled with the day of consumption and was asked to return the package with any capsules left, so that the compliance could be calculated"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity<br>  
            </p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
      </table>
    </div>
    <div>
      <table>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td style="vertical-align: top;">
            <p>Lozoff 2016</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td style="vertical-align: top;">
            <p>Low-dose iron supplementation in infancy and iron status at 9 months of age</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>"Infants born to women in a pregnancy iron supplementation trial"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why<br>  
            </p>
          </td><td style="vertical-align: top;">
            <p>"Previous trials of iron supplementation in infancy did not consider maternal iron supplementation."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td style="vertical-align: top;">
            <p>"Women in the pregnancy RCT received information about the infancy study at routine prenatal visits. Sanhe Maternity and Child Health Care Center staff provided further information after delivery, answered questions, and obtained signed informed consent from those agreeing to participate...</p>
            <p>To help maintain masking, all families were informed that supplements</p>
            <p>might alter stool color and/or consistency"</p>
            <p>Cord blood collection</p>
            <p>"Cord-blood samples were obtained in the pregnancy RCT by sterile needle puncture immediately after cord clamping, which generally occurred within 60 s of delivery."</p>
            <p>Capillary blood collection</p>
            <p>"Finger stick samples (˜1.0 mL) at 9 mo were obtained by trained staff members using contact-activated lancets (BD Microtainer) and techniques to facilitate free blood flow, such as warming and gravity.</p>
            <p>Complete blood count</p>
            <p>"A complete blood count, including hemoglobin and mean corpuscular volume, was performed by using a Sysmex KX-21N Auto Hematology Analyzer (SYSMEX Corporation). In Sanhe, whole blood for zinc protoporphyrin (PP)/heme was stored at 4 &deg;C and protected from light; serum for other iron measures was stored at &ndash;20 &deg;C... transferred weekly to Peking University First Hospital where ZPP/heme was analyzed by using a hematofluorometer (AVIV Biomedical), SF and serum transferrin receptor (sTfR) by chemiluminescent immunoassay (Beckman Coulter Access 2 Immunoassay System; Beckman Coulter), and serum C-reactive protein by rate nephelometry (Hitachi 7600; Hitachi). Both laboratories maintained standard quality control procedures."</p>
            <p>Anthropometry</p>
            <p>"Infant weight, length, and head circumference were measured by trained obstetrical staff at birth and pediatric staff at 9 mo. On the basis of parental report, project staff recorded reasons for hospitalizations and doctor visits between birth and 9 mo."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>"Finger stick samples ... were obtained by trained staff members...</p>
            <p>Infant weight, length, and head circumference were measured by</p>
            <p>trained obstetrical staff at birth and pediatric staff at 9 mo"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>"Enrollment and informed consent... at routine prenatal visits... Families were initially provided with 1 box of supplement (ten 15-mL bottles/box) and instructed to return for more as needed"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>supplementation was home-based</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td style="vertical-align: top;">
            <p>"infants were randomly assigned to a single daily dose of ˜1 mg Fe/(kg/d) of elemental iron as iron proteinsuccinylate oral solution (Ferplex, Italfarmico, S.p.A., Milan, Italy) from 6 wk to 9 mo or an equal volume of carrier alone."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity<br>  
            </p>
          </td><td style="vertical-align: top;">
            <p>"Staff recorded the number of boxes distributed and bottles returned. Each box provided enough daily supplements for; 10 wk for infants aged &lt; 6 mo and 5 wk for infants aged &ge; 6 mo... intended to monitor adherence by having parents mark a calendar each day they gave supplement, but only 126 calendars were returned with usable data.</p>
            <p>Therefore, we estimated adherence by the number of bottles received, calculated as bottles distributed minus bottles returned. Infants with IDA at 9 mo were prescribed therapeutic doses of iron per local practice."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity </p>
          </td><td style="vertical-align: top;">
            <p>"Only 15/1276 (1.2%) received &ge; 40 bottles as planned. The few available calendars indicated that many families did not give supplements daily, with a</p>
            <p>wide range between first and last dose regardless of number of bottles received."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td style="vertical-align: top;">
            <p>Hamza 2014</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td style="vertical-align: top;">
            <p>Iron supplementation and recurrent upper respiratory tract infections (URTIs) in Egyptian children</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>Children aged 6&ndash;15 years with a history of recurrent upper respiratory tract infections and iron deficiency (serum ferritin &lt;30 ng/mL)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>To determine whether iron supplementation in iron-deficient children reduces the frequency and severity of recurrent upper respiratory tract infections (URTIs)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td style="vertical-align: top;">
            <p>Ferrous sulfate syrup (specific dose not detailed)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>- Participants identified with recurrent URTIs and serum ferritin &lt;30 ng/mL<br> - Iron supplementation provided over 3 months<br> - Follow-up of infection rate and severity pre- and post-supplementation<br> - Assessment of hemoglobin and ferritin levels</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>n/a</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>Individually administered (presumably at home)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>Study conducted in Egypt (exact clinical setting not specified)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td style="vertical-align: top;">
            <p>3 months of daily iron supplementation; specific dosage not reported</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td style="vertical-align: top;">
            <p>n/a</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td style="vertical-align: top;">
            <p>n/a</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity </p>
          </td><td style="vertical-align: top;">
            <p>n/a</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td style="vertical-align: top;">
            <p>n/a</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author </p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>Singh 2014</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name<br>  
            </p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>The effect of iron folic acid tablets or iron fortified foods on the iron status of adolescent females in India<br>  
            </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>102 non-pregnant moderately anaemic (8 g/dL to 10.9 g/dL Hb) adolescent females</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why<br>  
            </p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>to compare the impact of dietary iron and commercially available iron among adolescent girls</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)<br>  
            </p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"Intervention group (A) received pearl millet based iron rich product of 100g (15 mg non-heme iron) per day with 200ml lemon water, Intervention group (B) received iron folic acid tablets (60 mg elemental iron) and group (C) remained as a control group hence received no supplementation during the course of intervention program of 45 days."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>Demographic information<br> "open-ended questionnaire was used to collect the background information of the subjects pertaining to the age, economic status, and educational qualification"<br> Hb determination<br> "Hemoglobin level of the selected subjects was estimated by Sahli&rsquo;s method [<a href="#422217185170333092">7</a>] before and after the intervention."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>&mdash;<br>  
            </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>&mdash;<br>  
            </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>College of Home Science, SKRAU, Bikaner, Rajasthan, India </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much<br>  
            </p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>The intervention group received iron folic acid tablets containing 60 mg elemental iron for 45 days,</p>
            <p>the control group received no intervention.</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>&mdash;<br>  
            </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>&mdash;<br>  
            </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>&mdash;<br>  
            </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity<br>  
            </p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>each intervention group had 15 girls on the final sampling day (personal communication)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td style="vertical-align: top;">
            <p>Nogueira Arcanjo 2013</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td style="vertical-align: top;">
            <p>Daily iron supplementation for treatment of anaemia in infants</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>infants aged 12-24 months</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>to compare efficacy of daily vs weekly supplementation in reducing anaemia prevalence</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td style="vertical-align: top;">
            <p>"Group A (intervention) was allocated 25mg elemental iron in liquid form (25mg/ml) once weekly; Group B (intervention) received 12.5 mg elemental iron once daily; Group C (control) received 0.5 ml of a natural color additive, annatto (Bixa orel- lana L.), daily, diluted in the quantity of 0.2 ml/l."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>"The liquid was squirted into the child&rsquo;s mouth using a plas- tic medical syringe with scale by class teachers."... "The main outcome of the study to be analyzed was hemoglobin values, for which two biochemical evaluations were performed, before and after intervention. Capillary blood samples were taken from a finger prick using aseptic techniques. Hemoglobin concentrations were promptly analyzed with a portable HemoCue B-hemoglobin photometer (Hb 301- HemoCue AB, A ̈ ngelholm, Sweden). Anemia was defined as Hb &lt;11.0 g/dl [6].</p>
            <p>On enrollment, the mothers were interviewed to define general characteristics of the children. The interviewer collected data on gender, infant&rsquo;s age, weight (determined using portable electronic scales&mdash;Plena; Rio de Janeiro, Brazil&mdash;accurate to 0.1 kg), mother&rsquo;s employment, mother&rsquo;s schooling, family income, access to public sewage system and water supply, birthweight, prematurity and recent hospital admission."</p>
            <p>"In parallel with the intervention, mothers from the three groups participated in fortnightly workshops held at local community centers that consisted of an educational component as advocated by WHO [6]: a medical professional explaining the effects of anemia on infants and their development; educa- tional sessions with nutritionists presenting the importance of diet diversification and locally avail- able foodstuffs rich in different micronutrients; and a brochure on iron-rich foods, and foods that enhance the absorption or utilization of iron"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>class teachers</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>group (cluster)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>daycare centers</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td style="vertical-align: top;">
            <p>Group A: 25mg/ml once weekly; Group B (intervention): 12.5 mg elemental iron once daily; Group C (control): 0.5 ml of a natural color additive, annatto (Bixa orellana L.), daily, diluted in the quantity of 0.2 ml/l</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity<br>  
            </p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity<br>  
            </p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>Chen 2013</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"Effect of simultaneous supplementation of vitamin A and iron on diarrheal and respiratory tract infection in preschool children in Chengdu City, China"<br>  
            </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"445 preschoolers, ages 3 to 6 y old"<br>  
            </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"...to investigate whether vitamin A combined with iron supplementation for preschool children resulted in improved changes in children&rsquo;s infectious morbidity."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"Four different intervention styles were performed in the study and children in each kindergarten were randomly recruited into one of the four groups. Group I received a 200,000 IU vitamin A capsule (as retinol) just one time initially [<a href="#422217458303934705">8</a>]; group II received ferrous sulfate (element Fe 1&ndash;2 mg/kg) once daily for 6 mo [<a href="#422217471685599749">9</a>]; group III received a 200,000 IU vitamin A capsule once initially and ferrous sulfate (element Fe 1&ndash;2 mg/kg) once daily for 6 mo; group IV, as the placebo-control group, received neither vitamin A nor ferrous sulfate. Ferrous sulfate was given to each child in groups II and III at afternoon snack time, 5 d/w throughout the study period. No ferrous sulfate intervention took place during school holidays or public holidays, and the ferrous sulfate was provided for 120 school days (the equivalent of 24 wk)."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>Anthropometric measurements<br> "Anthropometric examinations in each nursery were conducted by the same trained anthropometrist (N = four) from Chengdu Women and Children&rsquo;s Central Hospital at baseline and follow-up (6-mo) time points using standardized techniques to eliminate intra-examiner error...Weight was recorded using a weighing scale (100Med, Beijing, China) to the nearest 100 g with children in minimum clothing and bare feet. Similarly, height (&gt; 3 y old)/length (&lt;3 y) was measured in the standard position by the same standing scale (100Med) or a supine position by a supine scale (Haode, Guangzhou, China) to the nearest 0.1 cm. By using reference data from WHO (2005), the Z scores were calculated for height for age, weight for height, and weight for age. All indices were computed using Anthro (2005) for the personal computer, as recommended by the WHO (http://www.who.int/childgrowth/software/en/)."<br>
              <br> Haematology<br> "At the beginning and end of the 6-mo period, two blood samples (about 3 mL) were collected by venipuncture of an antecubital vein from each child before breakfast. One milliliter was drawn into a container containing heparin to measure Hb by the hemoglobincyanide method [<a href="#422217809888585116">10</a>] (Maker, Chengdu, China)....The remaining blood was centrifuged at 3000g for 5 min at room temperature. The blood samples were immediately stored at 4&deg;C to prevent micro-hemolysis and separated within 5 h. The centrifuged serum samples were divided into aliquots and immediately transported to the laboratory and stored at -20&deg;C. The serum samples prepared for retinol measurement were protected from light. The concentrations of SF [<a href="#422217829520549278">11</a>] were measured using a commercial enzyme-linked immunosorbent assay (Sunbiote, Shanghai, China), sTfR [<a href="#422217858520229307">12</a>] by microparticle-enhanced immunoassay (Sunbiote, Shanghai, China), CRP by particle-enhanced immunoturbidimetry (Sunbiote, Shanghai, China). Serum retinol concentration was determined by using high-performance liquid chromatography according to a previously described method [<a href="#422217892021446165">13</a>] with slight modification...Other biochemical indices were analyzed in Clinical Laboratory Center of Chengdu Women and Children&rsquo;s Central Hospital."<br>
              <br> Morbidity<br> "...morbidity data were based on self-reported infection status (respiratory, diarrhea, and parasite status) obtained through personnel interviews with parents or caregivers of the children in the previous 2 wk. Information also was collected at this baseline visit regarding the number of household members, their ages, education levels, income, household construction materials, the source and quality of household water, the type of household sanitation facilities, and household possessions. Mothers or caretakers also were interviewed regarding children&rsquo;s dietary patterns...At the same time, parents or guardians also were informed about the standardized checklist that would be used by the health care workers to record the morbidity data throughout the randomized controlled trial and were requested to inform the health care workers if their child had experienced any of the symptoms on the standardized checklist. The symptoms recorded were respiratory-related illnesses (including at least runny nose, cough, or sore throat), fever, skin rash, other illnesses, and diarrhea-related illnesses (including at least diarrhea, vomiting, nausea, or stomach pain). Diarrhea was defined as the passage of loose or liquid stools and a high stool frequency (i.e., &gt;3 stools/d). A morbidity episode was defined as an event of morbidity symptoms with 3 illness-free days between events. If a child was absent from school, the reason for the absence was obtained retrospectively from the mother, guardian, or child and recorded on the standardized checklist by the teacher. Morbidity data were collected on each school day by the teacher for a maximum of 120 weekdays and on about 60 weekend days and several public holidays from retrospection"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"The distribution of tablets was performed by nursery managers...Anthropometric examinations in each nursery were conducted by the same trained anthropometrist (N = four) from Chengdu Women and Children&rsquo;s CentralHospital at baseline and follow-up....Serum retinol was measured by experienced examiners in the Pediatric Laboratory of Chongqing Medical University...children&rsquo;s dietary patterns. Project personnel who had received training in the application of a previously validated questionnaire used it to collect these data...standardized checklist...used by the health care workers to record the morbidity...Morbidity data were collected...by the teacher"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>&mdash;<br>  
              <br>  
            </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>intervention provided in nursery schools </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>Group I: 200,000 IU vitamin A capsule (as retinol) once initially</p>
            <p>Group II: ferrous sulphate (1 to 2 mg/kg element iron) once daily for 6 months</p>
            <p>Group III: 200,000 IU vitamin A capsule (as retinol) once initially and ferrous sulphate (1 to 2 mg/kg element iron) once daily for 6 months d</p>
            <p>Group IV: "placebo- control group" received neither vitamin A nor ferrous sulphate.</p>
            <p> 
            </p>
            <p>"Ferrous sulfate was given to each child in groups II and III at afternoon snack time, 5 d/w throughout the study period. No ferrous sulfate intervention took place during school holidays or public holidays, and the ferrous sulfate was provided for 120 school days (the equivalent of 24 wk)."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity<br>  
            </p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"Compliance of ferrous sulfate tablet was monitored using recording tables, in which teachers recorded whether the child consumed &ldquo;all&rdquo; or &ldquo;none&rdquo; of the ferrous sulfate tablet. To avoid exchange of ferrous sulfate tablets among classmates, the four groups were physically separated by being moved to opposite corners of the classroom. Distribution and consumption of the ferrous sulfate tablet took place under close supervision; children in groups II and III were not allowed to leave the classroom or return to their original seats until their ferrous sulfate tablets were taken...If a child was absent or rejected the ferrous sulfate tablet, the amount eaten was recorded as &ldquo;none...Information on the acceptability of the ferrous sulfate tablet was obtained by a short questionnaire administered at the 6-mo assessment" </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity<br>  
            </p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"Retrospective data documented daily by caregivers indicated about 95% compliance of ferrous sulfate, suggesting that at least 95% of the preschool children in groups II and III took the ferrous sulfate during the study period." </p>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <p>
              <b>ASD</b>: autism spectrum disorder; <b>BMI</b>: body mass index; <b>CGI</b>: Clinical Global Impression; <b>CSHQ</b>: Children's Sleep Habits Questionnaire;<b> CRP</b>: C-reactive protein; <b>d</b>: day(s); <b>Hb</b>: haemoglobin; <b>ID</b>: iron deficiency; <b>IU</b>: international units; <b>mo</b>: month(s);<b> RBC</b>: red blood cell; <b>TIBC</b>: total iron binding capacity; <b>y</b>: year(s).</p>
          </td>
        </tr>
      </table>
    </div>
    <h2>References</h2>
    <ol>
      <li id="433424061920088765">
        <span publication-type="journal"><span person-group-type="author"><span><span>Baker</span> <span>RD</span></span>, <span><span>Greer</span> <span>FR</span></span>, <span>Committee on Nutrition</span></span>. <span>Diagnosis and prevention of iron deficiency and iron-deficiency anemia in infants and young children (0&ndash;3 years of age)</span>. <span>Pediatrics</span> <span>2010</span>;<span>126</span>(<span>5</span>):<span>1040-50</span>.</span>
      </li>
      <li id="433424035792196284">
        <span publication-type="book"><span person-group-type="author"><span><span>Mullen</span> <span>EM</span></span></span>. <span>Mullen scales of early learning</span>. <span>Circle Pines (MN)</span>: <span>American Guidance Services</span>, <span>1995</span>. </span>
      </li>
      <li id="422043635180836938">
        <span publication-type="journal"><span person-group-type="author"><span><span>Dosman</span> <span>CF</span></span>, <span><span>Brian</span> <span>JA</span></span>, <span><span>Drmic</span> <span>IE</span></span>, <span><span>Senthilselvan</span> <span>A</span></span>, <span><span>Harford</span> <span>MM</span></span>, <span><span>Smith</span> <span>RW</span></span>, et al</span>. <span>Children with autism: effect of iron supplementation on sleep and ferritin</span>. <span>Pediatric neurology</span> <span>2007</span>;<span>36</span>(<span>3</span>):<span>152-8</span>. [DOI: <a href="https://doi.org/https://doi.org/10.1016/j.pediatrneurol.2006.11.004">https://doi.org/10.1016/j.pediatrneurol.2006.11.004</a>]</span>
      </li>
      <li id="421543703008924230">
        <span publication-type="journal"><span person-group-type="author"><span><span>Mercuri</span> <span>E</span></span>, <span><span>Haataja</span> <span>L</span></span>, <span><span>Dubowitz</span> <span>L</span></span></span>. <span>Neurological assessment in normal young infants</span>. <span>Clinics in Developmental Medicine</span> <span>2007</span>;<span>176</span>(<span>1</span>):<span>24-3</span>.</span>
      </li>
      <li id="422086376837873942">
        <span publication-type="book-section"><span person-group-type="author"><span><span>Mercuri</span> <span>E</span></span>, <span><span>Haataja</span> <span>L</span></span>, <span><span>Dubowitz</span> <span>L</span></span></span>. <span>Neurological assessment in normal young infants</span>. In: <span>Neurological assessment in the first two years of life.</span>. 1st edition. <span>London</span>: <span>Mac Keith Press</span>, <span>2008</span>:<span>24-37</span>.</span>
      </li>
      <li id="422243992020739369">
        <span publication-type="journal"><span person-group-type="author"><span><span>Morris</span> <span>NM</span></span>, <span><span>Udry</span> <span>JR</span></span></span>. <span>Validation of a self-administered instrument to assess stage of adolescent development</span>. <span>Journal of Youth and Adolescence</span> <span>1980</span>;<span>9</span>(<span>3</span>):<span>217-80</span>. [DOI: <a href="https://doi.org/10.1007/BF02088471">10.1007/BF02088471</a>]</span>
      </li>
      <li id="422217185170333092">
        <span publication-type="journal"><span person-group-type="author"><span><span>Anand</span> <span>H</span></span>, <span><span>Mir</span> <span>R</span></span>, <span><span>Saxena</span> <span>R</span></span></span>. <span>Hemoglobin color scale a diagnostic dilemma</span>. <span>Indian Journal of Pathology and Microbiology. 2009 Jul 1;52(3):360.</span> <span>2009</span>;<span>52</span>(<span>3</span>):<span>360</span>. [DOI: <a href="https://doi.org/10.4103/0377-4929.54994">10.4103/0377-4929.54994</a>]</span>
      </li>
      <li id="422217458303934705">
        <span publication-type="journal"><span person-group-type="author"><span><span>Ross</span> <span>DA</span></span></span>. <span>Recommendations for vitamin A supplementation</span>. <span>Journal of Nutrition</span> <span>2002</span>;<span>132</span>(<span>9</span>):<span>2902S-6S</span>. [DOI: <a href="https://doi.org/10.1093/jn/132.9.2902S">10.1093/jn/132.9.2902S</a>]</span>
      </li>
      <li id="422217471685599749">
        <span publication-type="journal"><span person-group-type="author"><span><span>Stoltzfus</span> <span>RJ</span></span></span>. <span>Iron interventions for women and children in low-income countries</span>. <span>Journal of Nutrition</span> <span>2011</span>;<span>141</span>(<span>4</span>):<span>756S-62S</span>. [DOI: <a href="https://doi.org/10.3945/jn.110.128793">10.3945/jn.110.128793</a>]</span>
      </li>
      <li id="422217809888585116">
        <span publication-type="journal"><span person-group-type="author"><span><span>Zwart</span> <span>A</span></span>, <span><span>Van Assendelft</span> <span>OW</span></span>, <span><span>Bull</span> <span>BS</span></span>, <span><span>England</span> <span>JM</span></span>, <span><span>Lewis</span> <span>SM</span></span>, <span><span>Zijlstra</span> <span>WG</span></span></span>. <span>Recommendations for reference method for haemoglobinometry in human blood (ICSH standard 1995) and specifications for international haemiglobinocyanide standard</span>. <span>Journal of Clinical Pathology</span> <span>1996</span>;<span>49</span>(<span>4</span>):<span>271</span>. [DOI: <a href="https://doi.org/10.1136/jcp.49.4.271">10.1136/jcp.49.4.271</a>]</span>
      </li>
      <li id="422217829520549278">
        <span publication-type="journal"><span person-group-type="author"><span><span>Rohner</span> <span>F</span></span>, <span><span>Zeder</span> <span>C</span></span>, <span><span>Zimmermann</span> <span>MB</span></span>, <span><span>Hurrell</span> <span>RF</span></span></span>. <span>Comparison of manual and automated ELISA methods for serum ferritin analysis</span>. <span>Journal of Clinical Laboratory Analysis</span> <span>2005</span>;<span>19</span>(<span>5</span>):<span>196-8</span>. [DOI: <a href="https://doi.org/10.1002/jcla.20077">10.1002/jcla.20077</a>]</span>
      </li>
      <li id="422217858520229307">
        <span publication-type="journal"><span person-group-type="author"><span><span>Wians Jr</span> <span>FH</span></span>, <span><span>Urban</span> <span>JE</span></span>, <span><span>Kroft</span> <span>SH</span></span>, <span><span>Keffer</span> <span>JH</span></span></span>. <span>Soluble transferrin receptor (sTfR) concentration quantified using two sTfR kits: analytical and clinical performance characteristics</span>. <span>Clinica Chimica Acta</span> <span>2001</span>;<span>303</span>(<span>1-2</span>):<span>75-81</span>. [DOI: <a href="https://doi.org/10.1016/S0009-8981(00)00376-4">10.1016/S0009-8981(00)00376-4</a>]</span>
      </li>
      <li id="422217892021446165">
        <span publication-type="journal"><span person-group-type="author"><span><span>Hariharan</span> <span>M</span></span>, <span><span>VanNoord</span> <span>TJ</span></span>, <span><span>Greden</span> <span>JF</span></span></span>. <span>A high-performance liquid-chromatographic method for routine simultaneous determination of nicotine and cotinine in plasma</span>. <span>Clinical Chemistry</span> <span>1988</span>;<span>34</span>(<span>4</span>):<span>724-9</span>.</span>
      </li>
    </ol>
  </body>
</html>
